Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can MIRCERA keep anemia in check for kidney patients?

NCT ID NCT02567188

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times

Summary

This study followed 144 adults with chronic kidney disease (stages 3-4) who were not yet on dialysis and were already taking MIRCERA for anemia. Researchers tracked their hemoglobin levels and any changes in treatment over 12 months to see how well the drug works in everyday medical practice. The goal was to understand if MIRCERA helps maintain safe and stable red blood cell levels without major fluctuations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Study site

    Angeholm, S-262 81, Sweden

  • Study site

    Bollnäs, 821 81, Sweden

  • Study site

    Eskilstuna, 63188, Sweden

  • Study site

    Gävle, 80187, Sweden

  • Study site

    Gothenburg, 41345, Sweden

  • Study site

    Gothenburg, S-402 76, Sweden

  • Study site

    Huddinge, 14186, Sweden

  • Study site

    Jönköping, 55185, Sweden

  • Study site

    Karlshamn, S-374 80, Sweden

  • Study site

    Karlstad, 65185, Sweden

  • Study site

    Kristianstad, 29185, Sweden

  • Study site

    Linköping, S-581 85, Sweden

  • Study site

    Mölndal, S-431 80, Sweden

  • Study site

    Norrköping, 60182, Sweden

  • Study site

    Skövde, 54185, Sweden

  • Study site

    Stockholm, 17176, Sweden

  • Study site

    Stockholm, 18288, Sweden

  • Study site

    Umeå, 90185, Sweden

  • Study site

    Värnamo, 33185, Sweden

  • Study site

    Västervik, 59381, Sweden

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MIRCERA (methoxy polyethylene glycol-epoetin beta)

What this could lead to

If successful, this study could confirm that MIRCERA helps maintain stable hemoglobin levels in pre-dialysis CKD patients, supporting its use for anemia management.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment, only monitors existing use.

Conditions

The condition(s) this trial relates to.

anemia chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.